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Section/topic # Checklist item Reported in main text
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
p. 11 and Tables 1-3 Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12) .
p. 11-and Tables S5-S6 in the OSD Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.
p. 12 and Table 4 Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.
p. 12 and Table 4 Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15) . p. [11] [12] and Tables  S5-S6 in the OSD Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16] ).
p. 12-13 and Table 5 DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).
p. 14-17
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). * Three studies reported in the systematic review were excluded from further analyses, either because of the priority order followed for selecting studies applying the same assay to different biological specimens (2 studies), or because measures based on culture were superseded by measures based on polymerase chain reaction (1 study). FSWs, female sex workers. NA, not applicable. The same population may have contributed different measures for both current infection and ever (seropositivity using antibody testing) infection. * Medians and ranges were calculated based on the stratified prevalence measures. † Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size (here, prevalence) across studies. ‡ I 2 : a measure assessing the magnitude of between-study variation that is due to differences in effect size (here, prevalence) across studies rather than chance. § Prediction interval: a measure estimating the 95% interval of the distribution of true effect sizes (here, prevalence measures). ‖ Meta-analyses were performed if at least three studies were available. ¶ Ever infection indicates seropositivity using antibody testing. CI, confidence interval. FSWs, female sex workers. The same population may have contributed different measures for both current infection and ever (seropositivity using antibody testing) infection. * Medians and ranges were calculated based on the stratified prevalence measures. † Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size (here, prevalence) across studies. ‡ I 2 : a measure assessing the magnitude of between-study variation that is due to differences in effect size (here, prevalence) across studies rather than chance. § Prediction interval: a measure estimating the 95% interval of the distribution of true effect sizes (here, prevalence measures). ‖ Ever infection indicates seropositivity using antibody testing. CI, confidence interval. FSWs, female sex workers. 
